![]() The contractions push the stool through your system.īulk-forming laxatives may take a few days to work, but they are safe for long-term use.īulk-forming laxatives often come in the form of powder or granules that you mix with water or other liquid and take by mouth. This can help to produce muscle contractions in the intestines, which means the muscles tighten or squeeze. They work by pulling fluid into the intestines to make the stool softer and bulkier. Bulk-forming laxativesīulk-forming laxatives are also known as fiber supplements. These products may differ in how fast they work and what side effects they may cause. ![]() This is because with brand-name products, the manufacturer may sell different products containing different laxatives under the same brand name. When looking for an OTC laxative, it’s helpful to be familiar with the generic name of the medication. All of these laxatives are available as generics, and most are available as brand-name products as well. ![]() The main types of laxatives are listed below. These include:Įach type of laxative works in a slightly different way to relieve constipation. Milder cases of constipation can often be treated using OTC medications, which are called laxatives. The most common treatment-related adverse events among the study groups were nausea and diarrhea.Over-the-counter constipation medications The spectrum of symptoms that constitute IBS-C, including abdominal pain and discomfort, bloating and constipation-related complaints, significantly improved during the 48-week treatment period. The study found that lubiprostone is effective and well tolerated in adults with IBS-C for up to one year. For this study, however, participants all received lubiprostone no placebos were given. Many of its 476 participants also took part in the phase III trials. This 48-week study looked at the efficacy and safety of lubiprostone. Lubiprostone also improved stool consistency.Īdditionally, Chey will present findings at DDW from a follow-on study related to the two phase III trials. By week four, 32 percent said they experienced relief of global IBS-C symptoms - abdominal pain, bloating, constipation severity and straining during bowel movements. Each participant kept an electronic diary to report weekly outcomes of IBS-C symptoms.Īfter one week, 20 percent of the lubiprostone participants reported moderate to significant relief of symptoms. These trials compared lubiprostone versus a placebo during the course of 12 weeks. The supplemental New Drug Application for AMITIZA - which also is approved by the FDA for treatment of chronic idiopathic constipation - was based on two phase III, multi-center trials involving 1,154 participants. Unfortunately, we just haven't had enough men represented in these studies to make a firm decision on treatment using this drug," notes Chey. "Although AMITIZA is only approved for use in women with IBS-C, it doesn't mean that the drug doesn't work for men. Since the majority of patients with IBS are women, studies involving IBS tend to be made up of predominately female participants - more than 80 percent in most cases, Chey estimates. IBS-C is more common among older adults, while IBS-D tends to be seen more in younger patients. Most patients with IBS tend to fall into two categories: IBS-C or IBS with diarrhea. And, he says, most over-the-counter medicines commonly used to treat symptoms - fiber, laxatives and stool stimulants - don't address the bloating and pain associated with IBS. While IBS is the second-leading cause of work absenteeism behind the common cold, Chey says fewer than half of patients with IBS seek medical treatment. IBS, an often painful disorder of the lower intestine, affects between 10 to 15 percent of the U.S. "Right now, it is the only FDA-approved treatment available that addresses the entire clinical spectrum of symptoms related to IBS-C." "We found that individuals who were treated with AMITIZA were nearly twice as likely to experience improvement in their IBS symptoms compared to individuals who were treated with placebo," says Chey, director of the Gastrointestinal Physiology Laboratory and professor of internal medicine at the U-M Medical School. Results from these studies will be presented on May 18 and May 19 at Digestive Diseases Week in San Diego. Chey, M.D., the studies show that lubiprostone significantly improves all of the symptoms associated with IBS-C in many women. Food and Drug Administration for use in women with IBS plus constipation, thanks in part to University of Michigan Health System research that demonstrated the safety and efficacy of the drug for treatment of IBS-C. Lubiprostone, known by the brand name AMITIZA®, was just approved by the U.S.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |